Amgen Stock Hits Day Low of $347.90 Amid Price Pressure

Amgen, Inc., a prominent player in the Pharmaceuticals & Biotechnology sector, experienced a notable decline of 3.1% on March 19, 2026, reaching an intraday low of USD 347.90. This performance contrasts with the S&P 500, which saw a modest decrease of 0.27% on the same day. Over the past week, Amgen's stock has dropped 7.34%, while its monthly performance reflects a decline of 7.85%. Despite these short-term challenges, the company has shown resilience over the past year, with a return of 9.81%, although this lags behind the S&P 500's 16.41% gain. Amgen's financial metrics indicate a strong management efficiency, highlighted by a return on capital employed (ROCE) of 22.31%. The company has also reported a robust interest coverage ratio of 777.03 and a significant increase in profits by 62.9% over the past year. With a market capitalization of USD 197,434 million, Amgen maintains a solid institutional ownership level of 81.91%, suggesting confidence in its long-term fundamentals.